Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olamkicept - Ferring Pharmaceuticals

Drug Profile

Olamkicept - Ferring Pharmaceuticals

Alternative Names: FE-301; FE-999301; TJ-301

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Conaris Research Institute
  • Developer Ferring Pharmaceuticals; I-MAB Biopharma; Leading Biopharm
  • Class Anti-inflammatories; Glycoproteins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory bowel diseases; Ulcerative colitis
  • Phase I Gastrointestinal disorders
  • No development reported Crohn's disease

Most Recent Events

  • 20 Feb 2024 Phase-I clinical trials in Gastrointestinal disorders in Germany (IV) (NCT06298032)
  • 07 Dec 2022 Olamkicept is still in phase II trials for Ulcerative colitis in Australia, China, South Korea, Taiwan (IV) (Ferring Pharmaceuticals website, December 2022)
  • 09 Jun 2022 Ferring Pharmaceuticals enters a strategic collaboration with I-Mab Biopharma to develop olamkicept in Inflammatory bowel disease and related inflammatory conditions
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top